Literature DB >> 22615281

Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.

Claire M Hull1, Josie E Parker, Oliver Bader, Michael Weig, Uwe Gross, Andrew G S Warrilow, Diane E Kelly, Steven L Kelly.   

Abstract

We identified a clinical isolate of Candida glabrata (CG156) exhibiting flocculent growth and cross-resistance to fluconazole (FLC), voriconazole (VRC), and amphotericin B (AMB), with MICs of >256, >256, and 32 μg ml(-1), respectively. Sterol analysis using gas chromatography-mass spectrometry (GC-MS) revealed that CG156 was a sterol 14α-demethylase (Erg11p) mutant, wherein 14α-methylated intermediates (lanosterol was >80% of the total) were the only detectable sterols. ERG11 sequencing indicated that CG156 harbored a single-amino-acid substitution (G315D) which nullified the function of native Erg11p. In heterologous expression studies using a doxycycline-regulatable Saccharomyces cerevisiae erg11 strain, wild-type C. glabrata Erg11p fully complemented the function of S. cerevisiae sterol 14α-demethylase, restoring growth and ergosterol synthesis in recombinant yeast; mutated CG156 Erg11p did not. CG156 was culturable using sterol-free, glucose-containing yeast minimal medium ((glc)YM). However, when grown on sterol-supplemented (glc)YM (with ergosta 7,22-dienol, ergosterol, cholestanol, cholesterol, Δ(7)-cholestenol, or desmosterol), CG156 cultures exhibited shorter lag phases, reached higher cell densities, and showed alterations in cellular sterol composition. Unlike comparator isolates (harboring wild-type ERG11) that became less sensitive to FLC and VRC when cultured on sterol-supplemented (glc)YM, facultative sterol uptake by CG156 did not affect its azole-resistant phenotype. Conversely, CG156 grown using (glc)YM with ergosterol (or with ergosta 7,22-dienol) showed increased sensitivity to AMB; CG156 grown using (glc)YM with cholesterol (or with cholestanol) became more resistant (MICs of 2 and >64 μg AMB ml(-1), respectively). Our results provide insights into the consequences of sterol uptake and metabolism on growth and antifungal resistance in C. glabrata.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22615281      PMCID: PMC3421581          DOI: 10.1128/AAC.06253-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains.

Authors:  S Maesaki; P Marichal; H Vanden Bossche; D Sanglard; S Kohno
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

3.  Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors.

Authors:  Quanbo Xiong; Saad A Hassan; William K Wilson; Xiang Y Han; Gregory S May; Jeffrey J Tarrand; Seiichi P T Matsuda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Sterol uptake in Candida glabrata: rescue of sterol auxotrophic strains.

Authors:  Martin Bard; Aaron M Sturm; Charles A Pierson; Shaleak Brown; Kristina M Rogers; Sarah Nabinger; James Eckstein; Robert Barbuch; N D Lees; Susan A Howell; Kevin C Hazen
Journal:  Diagn Microbiol Infect Dis       Date:  2005-08       Impact factor: 2.803

5.  Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.

Authors:  Patrick Vandeputte; Guy Tronchin; Thierry Bergès; Christophe Hennequin; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

6.  Isolation of cholesterol-dependent Candida glabrata from clinical specimens.

Authors:  Kevin C Hazen; Jamal Stei; Caroline Darracott; Aodhan Breathnach; Joanna May; Susan A Howell
Journal:  Diagn Microbiol Infect Dis       Date:  2005-05       Impact factor: 2.803

7.  Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth.

Authors:  Patrick Vandeputte; Guy Tronchin; Françoise Rocher; Gilles Renier; Thierry Bergès; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

8.  The Candida glabrata putative sterol transporter gene CgAUS1 protects cells against azoles in the presence of serum.

Authors:  Hironobu Nakayama; Koichi Tanabe; Martin Bard; Wesley Hodgson; Sung Wu; Daiki Takemori; Toshihiro Aoyama; N Selvamuthu Kumaraswami; Laurel Metzler; Yukie Takano; Hiroji Chibana; Masakazu Niimi
Journal:  J Antimicrob Chemother       Date:  2007-10-02       Impact factor: 5.790

9.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.

Authors:  Mikkel Krogh-Madsen; Maiken Cavling Arendrup; Lars Heslet; Jenny Dahl Knudsen
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

10.  Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.

Authors:  Sélène Ferrari; Françoise Ischer; David Calabrese; Brunella Posteraro; Maurizio Sanguinetti; Giovanni Fadda; Bettina Rohde; Christopher Bauser; Oliver Bader; Dominique Sanglard
Journal:  PLoS Pathog       Date:  2009-01-16       Impact factor: 6.823

View more
  43 in total

1.  Expression Patterns of ABC Transporter Genes in Fluconazole-Resistant Candida glabrata.

Authors:  Atefeh Abdollahi Gohar; Hamid Badali; Tahereh Shokohi; Mojtaba Nabili; Nasrin Amirrajab; Maryam Moazeni
Journal:  Mycopathologia       Date:  2016-10-15       Impact factor: 2.574

2.  Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast.

Authors:  Cigdem Balkan; Ilkcan Ercan; Esin Isik; Esra Sahin Akdeniz; Orhan Balcioglu; Marie Kodedová; Olga Zimmermannová; Muhammed Dundar; Hana Sychrová; Ahmet Koc
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  UPC2A is required for high-level azole antifungal resistance in Candida glabrata.

Authors:  Sarah G Whaley; Kelly E Caudle; John-Paul Vermitsky; Sean G Chadwick; Geoffrey Toner; Katherine S Barker; Scott E Gygax; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.

Authors:  Claire M Hull; Oliver Bader; Josie E Parker; Michael Weig; Uwe Gross; Andrew G S Warrilow; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

5.  Analysis of sphingolipids, sterols, and phospholipids in human pathogenic Cryptococcus strains.

Authors:  Ashutosh Singh; Andrew MacKenzie; Geoffrey Girnun; Maurizio Del Poeta
Journal:  J Lipid Res       Date:  2017-08-15       Impact factor: 5.922

6.  A CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts.

Authors:  Isabelle Accoceberry; Amandine Rougeron; Nicolas Biteau; Pauline Chevrel; Valérie Fitton-Ouhabi; Thierry Noël
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  The yeast pantothenate kinase Cab1 is a master regulator of sterol metabolism and of susceptibility to ergosterol biosynthesis inhibitors.

Authors:  Joy E Chiu; Jose Thekkiniath; Sameet Mehta; Christoph Müller; Franz Bracher; Choukri Ben Mamoun
Journal:  J Biol Chem       Date:  2019-08-13       Impact factor: 5.157

8.  ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait.

Authors:  Suhail Ahmad; Leena Joseph; Josie E Parker; Mohammad Asadzadeh; Steven L Kelly; Jacques F Meis; Ziauddin Khan
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.

Authors:  Ana Carolina R Souza; Beth Burgwyn Fuchs; Henrique M S Pinhati; Ricardo A Siqueira; Ferry Hagen; Jacques F Meis; Eleftherios Mylonakis; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

10.  Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications.

Authors:  A Forastiero; A C Mesa-Arango; A Alastruey-Izquierdo; L Alcazar-Fuoli; L Bernal-Martinez; T Pelaez; J F Lopez; J O Grimalt; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.